Cambridge Cognition Holdings plc
https://www.cambridgecognition.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cambridge Cognition Holdings plc
A Guide To Decentralized Clinical Trials
In Vivo looks at some of the benefits and challenges created by decentralized clinical trials, how technology is being applied, and how regulators and researchers are working to prove the efficiency and cost-effectiveness of DCT trials compared to traditional clinical trials.
Kintsugi’s AI Software Analyzes Voice For Signs Of Depression, Anxiety
Kintsugi is developing an AI-driven software that analyzes voice to detect depression and anxiety, offering clinicians an early screening tool in call centers, telehealth and remote monitoring.
Improving Clinical Trials In Psychiatric Health Care
Kiri Granger, Monument Therapeutics’ chief scientific officer and executive director, and one of In Vivo’s 2022 Rising Leaders, hopes to take the company to the next level by rejecting the conventional one-size-fits-all approach to psychiatric clinical trials.
UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions
Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.
Company Information
- Industry
- Digital Health
- Services
- Other Names / Subsidiaries
-
- Cambridge Cognition Ltd
- Cambridge Cognition Holdings Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice